Inhibition of mTOR by rapamycin enhances killing of CML cells by imatinib mesylate and overcomes certain forms of imatinib resistance.

被引：0

作者：

Halbur, L ^{[1
]}

Ly, C ^{[1
]}

Ong, ST ^{[1
]}

机构：

[1] Univ Calif Irvine, Dept Med, Dept Hematol Oncol, Irvine, CA USA

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

242

引用

页码：72A / 72A

页数：1

共 35 条

[31] A novel mechanism for imatinib mesylate (STI571) resistance in CML cells: Contribution of TC-PTP to modulating signals down-stream from the BCR-ABL fusion protein.
Shimizu, T
Miyakawa, Y
Iwata, S
Kuribara, A
Tiganis, T
Morimoto, C
Ikeda, Y
Kizaki, M
BLOOD, 2004, 104 (11) : 547A - 548A
[32] Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair
Majsterek, I
Sliwinski, T
Poplawski, T
Pytel, D
Kowalski, M
Slupianek, A
Skorski, T
Blasiak, J
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2006, 603 (01) : 74 - 82
[33] Imatinib mesylate (ST1571) abrogates the resistance to doxorubicin in K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek, I
Blasiak, J
Slupianek, A
Skorski, T
BLOOD, 2005, 106 (11) : 438A - 438A
[34] Inhibition of phosphotyrosine phosphatase-1B (PTP1B) induces resistance to the ABL kinase inhibitor imatinib mesylate (Gleevec®) in BCR-ABL positive leukemic cells.
Koyama, N
Koschmieder, S
Tyagi, S
Myloch, S
Nuernberger, H
Rossmanith, T
Hofmann, WK
Hoelzer, D
Ottmann, OG
BLOOD, 2004, 104 (11) : 576A - 577A
[35] Enhanced killing of chronic myelogenous leukemia cells by rapamycin and imatinib is associated with differential inhibition of 4E-BP1 and eIF4E phosphorylation and decreased protein expression by non-overlapping mechanisms.
Moore, JC
Ly, C
Luke, H
Ong, ST
BLOOD, 2004, 104 (11) : 550A - 550A

← 1 2 3 4 →